REGENXBIO Faces Securities Class Action Over Gene Therapy Misstatements
Securities lawsuit filed against $RGNX for allegedly misleading investors about RGX-111 gene therapy efficacy and safety. Lead plaintiff deadline April 14, 2026.
RGNXsecurities class actionmisleading statements